10-K: Gyrodyne Extends Liquidation to 2028 Amid Legal Appeals

Gyrodyne, LLC, a real estate company focused on property liquidation, has extended its estimated dissolution timeline to December 31, 2028, due to ongoing legal challenges and regulatory delays impacting its Flowerfield and Cortlandt Manor properties.

Summary

• Gyrodyne's primary business involves managing medical office and industrial properties and pursuing entitlements to maximize their value for eventual sale in Suffolk and Westchester Counties, New York.
• The company operates under a liquidation basis of accounting, with the strategic goal of dissolving after selling all real property assets, settling debts, and distributing proceeds to shareholders.
• The estimated liquidation timeline has been extended to December 31, 2028, from an earlier estimate of 2026, primarily due to ongoing legal proceedings (Article 78 Appeal) and regulatory delays.
• A Purchase and Sale Agreement for an approximately 49-acre parcel of the Flowerfield property with B2K Smithtown LLC is in place for a purchase price between $24,000,000 and $28,740,000, contingent on subdivision and site plan approval, with an estimated closing by October 2028 or June 2029.
• Estimated net assets in liquidation as of December 31, 2025, are $25,858,997, equating to approximately $11.76 per common share, a decrease from $30,596,313 ($13.91 per share) as of December 31, 2024.
• The decrease in estimated distributions is mainly attributable to an increase in estimated liquidation and operating costs (approximately $3.5 million for the timeline extension), a $4,020,222 closing credit to B2K for infrastructure, and higher retention bonuses and selling costs, partially offset by a $3,602,000 increase in real estate value.
• The company incurred approximately $380,000 in land entitlement costs in 2025 and estimates an additional $1.3 million through December 31, 2028.
• Occupancy rates for both Flowerfield Industrial Park and Cortlandt Medical Center were 82% as of December 31, 2025.
• Approximately 52% of the company's annual leasing revenue is up for renewal in 2026.
• Management believes the company will need additional capital to fund operations through 2028 and intends to modify existing loan facilities or seek new ones.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with a negative sentiment due to the significant decrease in estimated shareholder distributions, the extended liquidation timeline, and the ongoing legal and regulatory hurdles that introduce substantial uncertainty and increased costs. While a major property sale agreement is in place, its contingencies and the need for additional capital highlight persistent challenges.

Positives

• The Supreme Court of New York issued a ruling in favor of the company on October 11, 2024, dismissing the Article 78 petition in its entirety, although this decision is currently under appeal.
• A Purchase and Sale Agreement for an approximately 49-acre parcel of the Flowerfield property with B2K Smithtown LLC is in place for an estimated gross value of $28,740,000, contingent on necessary approvals.
• The net realizable value of real estate increased by $3,602,000 during 2025, indicating an appreciation in property values.
• The company is in compliance with its loan covenants as of December 31, 2025.
• The Cortlandt Manor property received designation for a Medical Oriented Zoning District (MOD) with a total density of 154,000 square feet (150,000 medical use, 4,000 retail use), enhancing its development potential.
• The Suffolk County Planning Commission approved Gyrodyne's Flowerfield subdivision application without conditions on August 2, 2017, simplifying the approval process at the Town of Smithtown's Planning Board to a simple majority vote.

Negatives

• Estimated liquidating distributions decreased from $13.91 per share as of December 31, 2024, to $11.76 per share as of December 31, 2025.
• The estimated liquidation timeline has been extended by two years, from 2026 to December 31, 2028, due to ongoing legal appeals and regulatory delays.
• The Article 78 Proceeding against the Flowerfield Subdivision Application is ongoing, with petitioners filing multiple appeals and motions to renew/reargue, prolonging the entitlement process.
• The B2K Agreement includes a $4,020,222 credit to B2K at closing for sewer treatment plant and on-site infrastructure costs, which will reduce the net proceeds from the sale.
• The company believes it will need additional capital to fund operations through 2028, and there is no assurance of securing loan modifications or new credit facilities on satisfactory terms.
• Approximately 52% of annual leasing revenue is up for renewal in 2026, posing a significant re-leasing risk in potentially challenging market conditions.
• Operating costs increased in 2025 ($2,057,276) compared to 2024 ($1,898,920), while rent and reimbursements slightly decreased ($3,050,479 in 2025 vs $3,105,989 in 2024).
• The company has a history of operating losses and anticipates future operating losses.
• The company's common shares are thinly traded and have substantially less liquidity, with a risk of potential delisting from Nasdaq.
• The company is subject to tenant concentration risk, with the three largest tenants representing 26%, 19%, and 11% of total rental income in 2025.
• The former controller resigned as a full-time employee as of February 28, 2025, requiring a consulting agreement and potentially a new hire, which could increase costs.

Risks

• Any delay or denial of required entitlements or permits (zoning, land use, environmental) would adversely impact property enhancement plans.
• Capital improvement costs and other expenses for property enhancements may be higher than projected, potentially making projects unfeasible or unprofitable.
• The company may not have sufficient funds available or be able to obtain financing for value-enhancement projects on favorable terms, if at all.
• Community opposition and adverse publicity from neighboring property owners, the public, or non-governmental organizations could delay or prevent essential approvals.
• The ongoing Article 78 Proceeding and any future litigation could result in further extensions of the timeline for securing entitlements, selling properties, and distributing net proceeds.
• Uncertainty exists regarding the exact timing and amount of any further distributions to shareholders, as estimates are based on assumptions and factors outside the company's control.
• Failure to find buyers for properties at expected sales prices or underestimation of costs associated with sales could delay or reduce distributions.
• Real estate market values are constantly changing and fluctuate with inflation, interest rates, supply and demand, property utilization trends, and other factors.
• Sale agreement provisions, including those in the B2K Agreement, allow purchasers to terminate agreements or make the purchase price contingent upon site plan approval, leading to potential delays or reduced proceeds.
• The illiquidity of real estate and lack of diversification may make it difficult to sell properties or achieve satisfactory returns within projected timelines.
• Land entitlement and liquidation costs or unpaid liabilities may be greater than expected, reducing distributions to shareholders.
• The company is subject to risks associated with proxy contests and other actions of activist shareholders, which can be costly and time-consuming.
• The Stipulation of Settlement prohibits selling properties at prices below December 2014 appraised values, potentially limiting available options for disposition.
• Risks incidental to real estate ownership and management include tenant non-performance, costly leasehold improvements, lease termination rights, and increases in maintenance, insurance, and operating costs.
• Shareholders may be liable to creditors for an amount up to the distribution received if the company's reserves for payments to creditors are inadequate under New York State's fraudulent conveyance laws.
• Existing properties may subject the company to known and unknown liabilities, including environmental contamination, for which there may be limited or no recourse to former owners.
• Adverse developments affecting the financial services industry could significantly impair the company's access to funding sources and credit arrangements.
• Changes in economic and capital markets conditions, including periods of deteriorating real estate industry fundamentals, may significantly affect results of operations and returns.
• Inability to maintain occupancy rates, tenant defaults, or lower-than-expected cash flow could reduce distributions.
• The company may be unable to renew expiring leases or re-lease vacant space on a timely basis or on attractive terms, especially with 52% of annual leasing revenue up for renewal in 2026.
• Risks associated with the financial condition of tenants, including potential bankruptcy, could lead to loss of rental payments.
• The loss of a major tenant could adversely affect the company's financial condition due to tenant concentration.
• Increased operating costs, such as for cleaning, utilities, and maintenance, may not be fully recoverable from tenants, reducing profitability.
• Some potential losses may not be covered by insurance, or coverage may be insufficient.
• The company may incur costs to comply with environmental laws and regulations, including potential future initiatives related to global warming/climate change.
• The Coronavirus pandemic and its residual effects may continue to adversely impact operations, timelines for approvals, and real property utilization trends.
• A sustained or further increase in inflation could adversely impact operating expenses, and higher interest rates could result in lower sales proceeds from future dispositions.
• The company's common shares are thinly traded, leading to potential volatility and difficulty for shareholders to dispose of shares, with a risk of delisting from Nasdaq.
• The value of the medical office park may be affected by factors in the healthcare industry, including regulatory changes, reimbursement policies, and competition.
• The company's investments are concentrated in a single industry (real estate) and geographically (New York metropolitan area), making it vulnerable to downturns in these specific sectors or regions.
• Risks associated with renovations and capital improvements include environmental problems, cost overruns, delays, and funding shortages.
• Cybersecurity risks and cyber incidents may disrupt operations, compromise confidential information, and damage business relationships.
• Mortgage indebtedness could adversely impact the value of shareholders' investment if property values fall or if refinancing is required during adverse economic conditions.
• Changes in federal tax law could adversely affect the tax treatment of distributions to shareholders.
• Loss of key management personnel (CEO/CFO Gary Fitlin, COO Peter Pitsiokos) or the need to hire additional staff could materially affect business operations.

Future Outlook

Gyrodyne anticipates completing its liquidation process by December 31, 2028, an extension from previous estimates, contingent on resolving ongoing legal appeals and securing final regulatory approvals for its Flowerfield and Cortlandt Manor properties. The company expects to need additional capital to fund operations through this extended period and is actively marketing its properties for sale, including a significant parcel under agreement with B2K Smithtown LLC, which is subject to site plan approval. Management aims to maximize shareholder returns through strategic asset dispositions and timely distributions, though the ultimate amounts and timing remain uncertain due to market conditions and legal contingencies.

Management Comments

• The Board and Management believe the aforementioned strategy will increase the aggregate value for such properties as a whole.
• We remain committed to (1) enhancing the net value of Flowerfield and Cortlandt Manor to maximize the returns for our shareholders, (2) completing the disposition of our assets, (3) making timely distributions to our shareholders, (4) managing capital and liquidity, (5) mitigating risks relating to interest rates and real estate cycles and (6) completing the liquidation of the Company.
• Management believes the Company will need additional capital to properly fund operations through the end of 2028 absent sufficient working capital raised through the combination of property sales or the modification of its existing credit facilities and or new credit facilities, or other alternative capital raising strategies.
• Gyrodyne remains confident in its defense of the appeal, the motion to renew and reargue and the motion to appeal the denial of the Petitioners motion to stay enforcement of the order.

Industry Context

StockSavvy.ai notes that Gyrodyne's strategy of enhancing property values through entitlements before sale aligns with a common real estate development approach to maximize returns, particularly in competitive New York metropolitan markets. However, the prolonged legal challenges and regulatory backlogs, exacerbated by lingering pandemic effects and labor shortages, highlight significant operational hurdles faced by developers in complex entitlement processes. The company's focus on medical office and industrial properties taps into sectors generally considered more resilient to remote work trends compared to traditional office spaces, yet it remains vulnerable to broader macroeconomic factors like elevated interest rates and inflation impacting commercial real estate valuations and financing availability.

Comparison to Industry Standards

• The company's 82% occupancy rate for both Flowerfield Industrial Park and Cortlandt Medical Center is comparable to average industrial and medical office occupancy rates in stable markets, though specific regional benchmarks are not provided for direct comparison.
• The 15% interest rate on the extended LLYR loan for general working capital appears significantly higher than typical commercial mortgage rates, suggesting a higher perceived risk or limited financing options for a company in liquidation. For example, prime rate plus 1.5% was the previous rate, and prime rate is typically much lower than 15%.
• The estimated distribution per share of $11.76, down from $13.91, indicates a decline in expected shareholder value, which would be assessed against the company's current share price and the performance of other small-cap real estate liquidation entities.

Management Changes

Corporate Governance

Legal Proceedings

• **Putative Class Action Lawsuit (Settlement)**: Settled on August 14, 2015, requiring property sales at or above their appraised values as of 2014. As of December 31, 2025, the aggregate appraised value of remaining unsold properties exceeded the respective 2014 appraised value.
• **Article 78 Proceeding (Flowerfield Subdivision)**: Commenced April 26, 2022, by the Incorporated Village of Head of the Harbor and other parties, seeking to annul the Town of Smithtown Planning Board's preliminary approval of the Flowerfield Subdivision Application. The Supreme Court of New York, Suffolk County, initially dismissed the petition on October 11, 2024. Petitioners filed a notice of appeal on October 28, 2024, and a motion to renew and reargue on November 12, 2024 (denied March 21, 2025). Further appeals were filed on April 16, 2025, and the original appeal was perfected on April 28, 2025. Gyrodyne and the Town of Smithtown are vigorously defending against these appeals and motions, believing the process will extend into 2028.

Related Party Transactions

• The company has leasing arrangements with a not-for-profit organization where former Chairman Paul Lamb served as Chairman and a director (without compensation).
• A Consolidated Lease Agreement signed in March 2022 extended the lease to December 2027, reflecting a below-market annual rent of $8,829 and a total commitment of $317,455.
• Rental revenue from this related party was $55,784 for the year ended December 31, 2025, and $54,160 for the year ended December 31, 2024.
• The independent members of the Board approved these leasing transactions.
• Paul Lamb is no longer considered a related person after November 5, 2025, following his non-re-election to the Board.

Stakeholder Impact

• **Shareholders**: Face reduced estimated liquidating distributions ($11.76/share vs. $13.91/share), an extended timeline for liquidation (to 2028), and uncertainty due to ongoing legal proceedings and capital needs. There is a potential for shareholders to be held liable for distributions if creditors' claims are not fully satisfied.
• **Employees/Management**: Benefit from a retention bonus plan designed to incentivize officers and employees through the liquidation process. Employment agreements for the CEO and COO include severance provisions. The former controller transitioned to a consulting role, potentially requiring a new hire.
• **Tenants**: May experience changes in property management or ownership as properties are sold. They are exposed to increased operating costs that may be passed through by the company. Healthcare tenants, in particular, are subject to extensive industry regulations and potential changes in reimbursement policies.
• **Creditors**: The company is actively managing its debt and seeking loan modifications. There is a risk of delayed or reduced payments if asset sales are delayed or proceeds are lower than expected. Shareholders could be liable for distributions if funds are insufficient to pay creditors.
• **Local Communities**: Are impacted by ongoing development entitlement processes, environmental concerns, and traffic/congestion issues raised by civic groups in the Article 78 Proceeding, which can lead to prolonged disputes and uncertainty regarding land use.

Next Steps

• Continue vigorous defense of the Article 78 appeal and other motions related to the Flowerfield Subdivision Application.
• Pursue final subdivision approval for Flowerfield, expected in Q3 2026.
• Pursue subdivision and site plan approval for Cortlandt Manor, expected in mid-2027.
• Market the remaining Flowerfield and Cortlandt Manor properties for sale as individual lots or combined.
• Seek to modify existing loan facilities or secure new credit facilities to fund operations through 2028.
• Complete the disposition of all real property assets.
• Settle any debts and claims against the company.
• Pay liquidating distributions to holders of common shares.
• Complete the dissolution of the company, delist shares from Nasdaq, and terminate SEC registration and reporting obligations.

Key Dates

Recommendation

The company is in a complex liquidation process with an extended timeline and reduced estimated distributions per share. While a significant property sale agreement is in place, it is highly contingent on regulatory approvals and ongoing legal challenges, introducing substantial uncertainty. The need for additional capital and the high percentage of leases up for renewal in 2026 add further risk. However, the company's real estate assets have seen an increase in value, and management is actively pursuing value enhancement and strategic sales. Given the inherent uncertainties and the extended timeline, a 'hold' recommendation is appropriate for existing investors, awaiting clearer resolution of legal proceedings and capital structure, while new investors should exercise extreme caution due to the speculative nature of a liquidation play with significant headwinds.

Keywords

Real Estate, Property Development, Liquidation, SEC Filing, 10-K, New York Real Estate, Commercial Real Estate, Medical Office Properties, Industrial Properties, Entitlements, Subdivision Approval, Site Plan Approval, Article 78 Proceeding, Litigation Risk, Shareholder Distributions, Asset Sales, Corporate Governance, Risk Factors, Financial Reporting, Nasdaq, B2K Smithtown LLC, Flowerfield, Cortlandt Manor